Checking procalcitonin suitability for prognosis and antimicrobial therapy monitoring in burn patients

• Autor(a) principal: Cabral, Luís
• Data de Publicação: 2018
• Outros Autores: Afreixo, Vera, Meireles, Rita, Vaz, Miguel, Chaves, Catarina, Caetano, Marisa, Almeida, Luís, Paiva, José Artur
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10773/24496
• topic: Burns; Sepsis; Procalcitonin; Prognosis; Antimicrobial stewardship

Due to greater infection susceptibility, sepsis is the main cause of death in burn patients. Quick diagnosis and patient stratification, early and appropriated antimicrobial therapy, and focus control are crucial for patients' survival. On the other hand, superfluous extension of therapy is associated with adverse events and arousal of microbial resistance. The use of biomarkers, necessarily coupled with close clinical examination, may predict outcomes, stratifying patients who need more intensive care, and monitor the efficacy of antimicrobial therapy, allowing faster de-escalation or stop, reducing the development of resistance and possibly the financial burden, without increasing mortality. The aim of this work is to check the suitability of procalcitonin (PCT) to fulfill these goals in a large sample of septic burn patients.